The department is also involved in a number of clinical trials and investigator initiated trials aimed at developing new treatments and improving existing therapies for hematological disorders. These trials offer patients access to the latest treatments and technologies, and contribute to the advancement of medical science in the field of hematology.
In addition to its reputation for providing outstanding care for patients with Blood disorders, the Department of Clinical Hematology and BMT at Tata Medical Center is also recognized for the enormous volume of patients it treats each year. The department sees a roughly two and a half thousand new patients annually with hematological malignancies and also benign hematological conditions such as thalassemias, bleeding disorders, thrombotic disorders and aplastic anemia.
The BMT program at Tata Medical Center is considered one of the most comprehensive programs in the country. The program offers both autologous and allogeneic transplant options, and the department has a team of highly experienced transplant physicians and nurses who provide personalized care to each patient. The program also has a dedicated stem cell lab, which offers apheresis and other stem cell processing services.
The department’s research program is focused on developing new and innovative therapies for hematological disorders, including bone marrow transplantation. The department’s researchers are involved in a wide range of projects, from basic research on the biology of hematological disorders to translational research aimed at developing new therapies and treatments for patients.
Department of Clinical Hematology and BMT at Tata Medical Center aims to be a world-class center for the diagnosis, treatment, and research of hematological disorders. With a team of highly qualified and experienced consultants, a strong focus on training and research, and a commitment to providing personalized care to each patient, the department is at the forefront of the fight against hematological disorders in India.